Toronto – December 20, 2022 – The Canadian Nuclear Isotope Council (CNIC) is pleased to announce a partnership with ARC Clean Technology (ARC). As a member of the CNIC, ARC joins 76+ organizations and companies in Canada’s isotope community that work together to advance Canada’s role in the global supply chain for nuclear isotopes. ARC is the first advanced small modular reactor (aSMR) company to join the CNIC.

Created in 2006 with offices in Saint John, New Brunswick and Washington, DC, ARC is a clean energy technology company developing the ARC-100, a 100 MW aSMR providing inherently safe, reliable, and low-cost carbon-free power.  The ARC-100 has been selected by NB Power for deployment at the Point Lepreau Nuclear Generating Station by the late 2020s, making it the first grid-scale Generation IV reactor to be deployed in Canada. As a fast neutron reactor, the ARC-100 is also capable of producing significant quantities of high-quality medical isotopes.

Sodium Fast Reactors, like the ARC-100, have both a high neutron flux and energy, allowing them to produce isotopes for use in targeted radionuclide therapy. Many isotopes, such as Actinium-225, can be produced more effectively in fast neutron spectrums. Combining medical isotopes from large capacity fast reactors with those being generated already in Canada in thermal reactors significantly adds to Canada’s ability to supply medical isotopes worldwide.

Now as a member of the CNIC, ARC demonstrates its commitment to promoting public awareness about the value of medical isotopes and supporting the Canadian Isotope Ecosystem. Already home to a network of producers, research and development facilities, and original equipment manufacturers, Canada’s Isotope Ecosystem possesses world-class knowledge and technology. The addition of ARC’s expertise to the Isotope Ecosystem will help secure Canada’s position in the global supply chain for medical isotopes.

“The world has relied on Canada as a source of medical isotopes and nuclear medicine technologies for decades. The CNIC was formed to encourage the innovation and investment necessary to maintain Canada’s standing as a leader in the world’s isotope supply,” said James Scongack, Chair of the CNIC. “Technology like the ARC-100 is a great example of outstanding innovation in the isotope industry, happening here in Canada. ARC’s expertise in nuclear innovation will complement the CNIC’s efforts and bolster Canada’s capacity to produce life-saving isotopes.”

In 2023, the CNIC will continue its mission to strengthen Canada’s Isotope Ecosystem and creating new opportunities for collaboration within the industry.

“ARC Clean Technology is pleased to join the CNIC and collaborate with its network of world-class facilities and experts in the Canadian medical isotope community,” said William Labbe, President & CEO of ARC . “If Canada is to maintain its position as a leader in global science and the production of important medical isotopes, we must also encourage innovation in nuclear technologies. The partnership of ARC with the CNIC is a significant step towards ensuring that Canada is a place where innovation can thrive.”

To learn more about ARC Clean Technology, click here: https://www.arc-cleantech.com/

About the Canadian Nuclear Isotope Council
The CNIC is a coalition of science, healthcare and nuclear-sector organizations to ensure Canada remains a world leader in the production of life-saving isotopes by bringing awareness and supporting long-term policies at the domestic and international level that will save countless lives and support health-care innovation for decades to come.

To learn more about the CNIC visit www.CanadianIsotopes.ca and follow us on, FacebookTwitter, and LinkedIn.

For more information, please contact:

Andrew Thiele
Executive Director
Canadian Nuclear Isotope Council
226-930-1869
canadianisotopes@gmail.com